Gross margin is expected to be approximately 72% for the third quarter of 2025, compared to 64% in the prior year period. “During the third ...

- Educational event for physicians by physicians; participants heard from an esteemed panel of experts, innovators, and guest speakers - - Global medtech leaders, Siemens Healthineers and Cook Medical ...

An update from Profound Medical ( ($TSE:PRN) ) is now available. Profound Medical Corp. announced record preliminary unaudited revenues for the ...

TORONTO, Oct. 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision ...

TORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (PROF) (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets ...

Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. Profound is commercializing TULSA-PRO®, a ...

Profound Medical (PROF) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook ...

TORONTO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable ...

- Global medtech leaders, Siemens Healthineers and Cook Medical, shared their common vision with Profound of creating a total diagnostic and interventional MR solution for prostate disease - TORONTO, ...

TORONTO, May 08, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (PROF) (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets ...